Valeant Pharmaceuticals Sign Deal For Intendis Dermatological Products in the United Kingdom

13 October 2006

Valeant Pharmaceuticals Ltd. announced that it has signed an agreement with Intendis GmBH for Valeant to sell a range of Intendis dermatological products, including Finacea®, a topical treatment for rosacea, which was launched on September 18, 2006, in the United Kingdom. The agreement, which became effective on September 1, 2006, enables Valeant to broaden its offering of dermatological products in the UK.

"Valeant currently has a strong portfolio of dermatology products in the UK, including Dermatix® and Efudex®"

said Chuck Bramlage, president of Valeant Pharmaceuticals Europe, Middle East and Asia division.

"This agreement expands our product portfolio and allows us to offer clinicians a range of treatments for many dermatological disorders. In addition, it enables Valeant to capitalize on the growth opportunity in one of the worldÕs largest dermatology markets."

In addition to Finacea®, Valeant will support all other Intendis products in the UK, including the 30g formulation of Skinoren® Cream, an acne treatment; Scheriproct®, a treatment for hemorrhoids, available as an ointment (30g) or a pack of 12 suppositories; and Ultrabase®, a moisturising cream available in a 50g tube or a 500g pump dispenser.

Valeant Pharmaceuticals Ltd have offices in Chineham Business Park, Basingstoke, Hampshire. It is a subsidiary of Valeant Pharmaceuticals International, with a global specialty pharmaceutical company based in the United States that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at www.valeant.com.

Rest of Basingstoke Business News